337 related articles for article (PubMed ID: 24710669)
1. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL
Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL
J Hepatol; 2014 Aug; 61(2):228-34. PubMed ID: 24713186
[TBL] [Abstract][Full Text] [Related]
3. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes.
Cacoub P; Bourliere M; Asselah T; De Ledinghen V; Mathurin P; Hézode C; Henry L; Stepanova M; Younossi ZM
Value Health; 2018 Oct; 21(10):1218-1225. PubMed ID: 30314623
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
5. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
Younossi ZM; Stepanova M; Nader F; Henry L
J Am Geriatr Soc; 2016 Feb; 64(2):386-93. PubMed ID: 26825683
[TBL] [Abstract][Full Text] [Related]
7. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
8. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
Younossi ZM; Stepanova M; Marcellin P; Afdhal N; Kowdley KV; Zeuzem S; Hunt SL
Hepatology; 2015 Jun; 61(6):1798-808. PubMed ID: 25627448
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.
Younossi ZM; Stepanova M; Chan HLY; Lee MH; Yu ML; Dan YY; Choi MS; Henry L
Medicine (Baltimore); 2016 Mar; 95(9):e2702. PubMed ID: 26945356
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens.
Stepanova M; Thompson A; Doyle J; Younossi I; de Avila L; Younossi ZM
J Infect Dis; 2018 Mar; 217(7):1033-1043. PubMed ID: 29293991
[TBL] [Abstract][Full Text] [Related]
12. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
Younossi ZM; Stepanova M; Henry L; Gane E; Jacobson IM; Lawitz E; Nelson D; Nader F; Hunt S
J Hepatol; 2014 Apr; 60(4):741-7. PubMed ID: 24333184
[TBL] [Abstract][Full Text] [Related]
13. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
Younossi ZM; Stepanova M; Sulkowski M; Foster GR; Reau N; Mangia A; Patel K; Bräu N; Roberts SK; Afdhal N; Nader F; Henry L; Hunt S
Clin Infect Dis; 2016 Oct; 63(8):1042-1048. PubMed ID: 27444413
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Jacobson I; Agarwal K; Hezode C; Nader F; Henry L; Hunt S
J Hepatol; 2016 Jul; 65(1):33-39. PubMed ID: 26956698
[TBL] [Abstract][Full Text] [Related]
15. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
[TBL] [Abstract][Full Text] [Related]
16. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
Younossi ZM; Stepanova M; Henry L; Nader F; Younossi Y; Hunt S
Medicine (Baltimore); 2016 Jul; 95(28):e4151. PubMed ID: 27428205
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Puoti M; Orkin C; Hunt SL
J Infect Dis; 2015 Aug; 212(3):367-77. PubMed ID: 25583164
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
Younossi ZM; Stepanova M; Henry L; Han KH; Ahn SH; Lim YS; Chuang WL; Kao JH; Nguyen KV; Lai CL; Chan HL; Wei L
J Viral Hepat; 2018 Dec; 25(12):1429-1437. PubMed ID: 29974665
[TBL] [Abstract][Full Text] [Related]
19. Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity.
Younossi ZM; Stepanova M; Esteban R; Jacobson I; Zeuzem S; Sulkowski M; Henry L; Nader F; Cable R; Afendy M; Hunt S
Medicine (Baltimore); 2017 Feb; 96(7):e5914. PubMed ID: 28207507
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
Pol S; Sulkowski MS; Hassanein T; Gane EJ; Liu L; Mo H; Doehle B; Kanwar B; Brainard D; Subramanian GM; Symonds WT; McHutchison JG; Nahass RG; Bennett M; Jacobson IM
Hepatology; 2015 Jul; 62(1):129-34. PubMed ID: 25847509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
